Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Innovative therapies for sepsis
Autore:
Krishnagopalan, S; Dellinger, RP;
Indirizzi:
Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Sect Crit Care Med, Chicago, IL 60612 USA Rush Med Coll Chicago IL USA 60612 t Crit Care Med, Chicago, IL 60612 USA Cook Cty Hosp, Chicago, IL 60612 USA Cook Cty Hosp Chicago IL USA 60612Cook Cty Hosp, Chicago, IL 60612 USA
Titolo Testata:
BIODRUGS
fascicolo: 10, volume: 15, anno: 2001,
pagine: 645 - 654
SICI:
1173-8804(2001)15:10<645:ITFS>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; INTERLEUKIN-1 RECEPTOR ANTAGONIST; FACTOR PATHWAY INHIBITOR; INFLAMMATORY RESPONSE SYNDROME; CONTROLLED MULTICENTER TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; DOUBLE-BLIND; MONOCLONAL-ANTIBODY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
81
Recensione:
Indirizzi per estratti:
Indirizzo: Dellinger, RP Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Sect CritCare Med, 1653 W Congress Pkwy,Room 979 Jelke, Chicago, IL 60612 USA Rush Med Coll 1653 W Congress Pkwy,Room 979 Jelke Chicago IL USA 60612
Citazione:
S. Krishnagopalan e R.P. Dellinger, "Innovative therapies for sepsis", BIODRUGS, 15(10), 2001, pp. 645-654

Abstract

Sepsis and septic shock continue to be a major cause of morbidity and mortality. Despite numerous advances in the supportive care of patients with sepsis, the overall mortality has changed little in the past 20 years. Many innovative therapies have been attempted in the field of sepsis, primarily aimed at stopping the cycle of cytokine activation which is part of the systemic inflammatory response. Therapies have also targeted other molecular mediators of inflammation and coagulation. Despite encouraging preliminary preclinical results, most of the early trials in sepsis research have failed to offer hope of improving survival with the use of these innovative therapies. Postulated reasons for the failure of clinical trials include the disparity between animal models and clinical reality, the heterogeneous nature of patient populations and sepsis, and the complexity of the inflammatory cascade. On a more hopeful note, three recent trials assessing corticosteroids, anti-tumour necrosis factor strategy and drotrecogin alfa. (rhAPC), respectively, have proclaimed positive results. However, only the drotrecogin alfa trial has been peer reviewed and published.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 09:26:00